medigraphic.com
ISSN 1561-3011 (Digital)

2021, Número 1

<< Anterior Siguiente >>

Rev Cubana Invest Bioméd 2021; 40 (1)


Aspectos biomoleculares de la prevención de la litogénesis biliar de colesterol

Piñol JFN, Clavería CNE, Segura FN, Velastegui BJC, Sánchez FEM

Idioma: Español
Referencias bibliográficas: 48
Paginas: 1-18
Archivo PDF: 350.22 Kb.


RESUMEN

Introducción: La litogénesis biliar, proceso de sobresaturación de colesterol en la bilis vesicular, es prevenible.
Objetivo: Describir las nuevas evidencias biomoleculares de la litogénesis biliar de colesterol como base de la futura terapia preventiva de la litiasis vesicular.
Método: Se realizó una revisión sistemática y crítica de las evidencias de impacto sobre la litogénesis biliar. Se consultaron artículos publicados entre 2015-2020 en las bases de datos PubMed, Medline, SciELO, LILACS y Elsevier.
Resultados: Se recuperaron evidencias actuales de los mecanismos biomoleculares relacionados con las futuras terapias preventivas de la litiasis vesicular, propuestos como fundamentos teóricos.
Conclusiones: La descripción actualizada de la litogénesis biliar de colesterol, con los nuevos conceptos biomoleculares incorporados, aporta a su comprensión el papel de los genes de receptores nucleares, la intervención de estos últimos y de los transportadores de la secreción biliar. Dirigida a médicos generales, cirujanos, gastroenterólogos y fisiólogos, la descripción actualizada de La litogénesis biliar impacta como nuevo paradigma con los conceptos biomoleculares que intervienen en pro de su prevención.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019;5(2):93-102. PMCID: PMC6728871

  2. Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. F1000Research. 2018;7(F1000 Faculty Rev):1529. PMCID: PMC6173119

  3. Zhang J-W, Xiong J-P, Xu W-Y, Sang X-T, Huang H-C, Bian J, et al. Fruits and vegetables consumption and the risk of gallstone disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(28):e16404-e. PMCID: PMC6641782

  4. Di Ciaula A, Wang DQH, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018;34(2):71-80. DOI: 10.1097/MOG.0000000000000423

  5. Piñol Jiménez FN, Ruiz Torres JF, Segura Fernández N, Proaño Toapanta PS, Sánchez Figueroa EM. La vesícula biliar como reservorio y protectora del tracto digestivo. Rev. Cubana Invest. Bioméd. 2020 [acceso: 09/04/2020]; 39(1). Disponible en: http://www.revibiomedica.sld.cu/index.php/ibi/article/view/259

  6. Rudling M, Laskar A, Straniero S. Gallbladder bile supersaturated with cholesterol in gallstone patients preferentially develops from shortage of bile acids. J Lipid Res. 2019;60(3):498-505. PMCID: PMC6399503

  7. Portincasa P, van Erpecum KJ, Di Ciaula A, Wang DQH. The physical presence of gallstone modulates ex vivo cholesterol crystallization pathways of human bile. Gastroenterology Report. 2018;7(1):32-41. DOI: 10.1093/gastro/goy044

  8. Chuang S-C, Hsi E, Lee K-T. Mucin genes in gallstone disease. Clinica Chimica Acta. 2012 [acceso: 13/03/2020]; 413(19):1466-71. Disponible en: http://www.sciencedirect.com/science/article/pii/S0009898112003178

  9. Cai J-S, Chen J-H. The Mechanism of Enterohepatic Circulation in the Formation of Gallstone Disease. J Membrane Biol. 2014;247(11):1067-82. DOI: 10.1007/s00232-014-9715-3

  10. Housset C, Chrétien Y, Debray D, Chignard N. Functions of the Gallbladder. Compr Physiol. 2016;6(3):1549-77. DOI: 10.1002/cphy.c150050

  11. Piñol JFN, Paniagua EM, Salvador PJC, Arciniega ÁDF. Hormonas y Neuropéptidos Gastrointestinales. 2.ª ed. La Habana: Editorial Ciencias Médicas; 2015. [acceso: 13/03/2020]. Disponible en: http://www.bvscuba.sld.cu/libro/hormonas-y-neuropeptidos-gastrointestinales-2da-ed/

  12. Rudling M, Laskar A, Straniero S. Gallbladder bile supersaturated with cholesterol in gallstone patients preferentially develops from shortage of bile acids. J Lipid Res. 2019;60(3):498-505. PMCID: PMC6399503

  13. Li H, Shen J, Wu T, Kuang J, Liu Q, Cheng S, et al. Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis. Front Pharmacol. 2019;10:548. PMCID: PMC6546903

  14. Kiriyama Y, Nochi H. The Biosynthesis, Signaling, and Neurological Functions of Bile Acids. Biomolecules. 2019 [acceso: 13/03/2020]; 9(6). Disponible en: https://www.mdpi.com/2218-273X/9/6/232

  15. Liu X, Guo GL, Kong B, Hilburn DB, Hubchak SC, Park S, et al. Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice. HEPATOLOGY. 2018;68(1):304-16. DOI: 10.1002/hep.29815

  16. Garcia M, Thirouard L, Sedès L, Monrose M, Holota H, Caira F, et al. Nuclear Receptor Metabolism of Bile Acids and Xenobiotics: A Coordinated Detoxification System with Impact on Health and Diseases. Int J Mol Sci. 2018 [acceso: 13/03/2020]; 19(11). Disponible en: https://www.mdpi.com/1422-0067/19/11/3630

  17. Yu DD, Andrali SS, Li H, Lin M, Huang W, Forman BM. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease. Bioorg Med Chem. 2016 [acceso: 13/03/2020]; 24(18):3986-93. Disponible en: http://www.sciencedirect.com/science/article/pii/S096808961630462X

  18. Chiang JYL, Ferrell JM. Bile Acids as Metabolic Regulators and Nutrient Sensors. Annu Rev Nutr. 2019;39(1):175-200. DOI: 10.1146/annurev-nutr-082018-124344

  19. Salic K, Kleemann R, Wilkins-Port C, McNulty J, Verschuren L, Palmer M. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One. 2019;14(6):e0218459-e. PMCID: PMC6590809

  20. Semmler G, Simbrunner B, Scheiner B, Schwabl P, Paternostro R, Bucsics T, et al. Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. J Gastroenterol Hepatol. 2019;34(12):2164-72. DOI: 10.1111/jgh.14700

  21. Van de Wiel SMW, Bijsmans ITGW, van Mil SWC, van de Graaf SFJ. Identification of FDA-approved drugs targeting the Farnesoid X Receptor. Sci Rep. 2019;9(1):2193. DOI: 10.1038/s41598-019-38668-7

  22. Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. HEPATOLOGY. 2018;67(5):1890-902. DOI: 10.1002/hep.29569

  23. Wang B, Tontonoz P. Liver X receptors in lipid signaling and membrane homeostasis. Nat Rev Endocrinol. 2018;14(8):452-63. DOI: 10.1038/s41574-018-0037-x

  24. Patel SB, Graf GA, Temel RE. ABCG5 and ABCG8: more than a defense against xenosterols. J Lipid Res. 2018;59(7):1103-13. PMCID: PMC6027916

  25. Ji G, Xu C, Sun H, Liu Q, Hu H, Gu A, et al. Organochloride pesticides induced hepatic ABCG5/G8 expression and lipogenesis in Chinese patients with gallstone disease. Oncotarget. 2016;7(23):33689-702. PMCID: PMC5085112

  26. Schulman IG. Liver X receptors link lipid metabolism and inflammation. FEBS Lett. 2017;591(19):2978-91. PMCID: PMC5638683

  27. Weikum ER, Liu X, Ortlund EA. The nuclear receptor superfamily: A structural perspective. Protein Sci. 2018;27(11):1876-92. DOI: 10.1002/pro.3496

  28. Jonker JW, Liddle C, Downes M. FXR and PXR: Potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol. 2012 [acceso: 13/03/2020]; 130(3):147-58. Disponible en: http://www.sciencedirect.com/science/article/pii/S0960076011001488

  29. Qin X, Wang X. Role of vitamin D receptor in the regulation of CYP3A gene expression. Acta Pharm Sin B. 2019 [acceso: 13/03/2020]; 9(6):1087-98. Disponible en: http://www.sciencedirect.com/science/article/pii/S2211383518312346

  30. Slijepcevic D, van de Graaf SFJ. Bile Acid Uptake Transporters as Targets for Therapy. Dig Dis. 2017 [acceso: 13/03/2020]; 35(3):251-8. Disponible en: https://www.karger.com/DOI/10.1159/000450983

  31. Henkel SA, Squires JH, Ayers M, Ganoza A, McKiernan P, Squires JE. Expanding etiology of progressive familial intrahepatic cholestasis. World J Hepatol. 2019;11(5):450-63. PMCID: PMC6547292

  32. Park HJ, Kim TH, Kim SW, Noh SH, Cho KJ, Choi C, et al. Functional characterization of ABCB4 mutations found in progressive familial intrahepatic cholestasis type 3. Sci Rep. 2016;6(1):26872. DOI: 10.1038/srep26872

  33. Zhan L, Pan Y-Z, Chen L, Zhang H, Zhang H, Song J, et al. Prevalence of ABCB4 polymorphisms in gallstone disease in han-Chinese population. Am J Transl Res. 2016;8(2):1218-27. PMCID: PMC4846965

  34. Gan L, Pan S, Cui J, Bai J, Jiang P, He Y. Functional analysis of the correlation between ABCB11 gene mutation and primary intrahepatic stone. Mol Med Rep. 2019;19(1):195-204. PMCID: PMC6297787

  35. Zein AA, Kaur R, Hussein TOK, Graf GA, Lee JY. ABCG5/G8: a structural view to pathophysiology of the hepatobiliary cholesterol secretion. Biochem Soc Trans. 2019;47(5):1259-68. DOI: 10.1042/BST20190130

  36. Luo Z-L, Cheng L, Wang T, Tang L-J, Tian F-Z, Xiang K, et al. Bile Acid Transporters Are Expressed and Heterogeneously Distributed in Rat Bile Ducts. Gut Liver. 2019;13(5):569-75. PMCID: PMC6743800

  37. Pineda M, Walterfang M, Patterson MC. Miglustat in Niemann-Pick disease type C patients: a review. Orphanet J Rare Dis. 2018;13(1):140. DOI: 10.1186/s13023-018-0844-0

  38. Ahmed O, Littmann K, Gustafsson U, Pramfalk C, Öörni K, Larsson L, et al. Ezetimibe in Combination with Simvastatin Reduces Remnant Cholesterol without Affecting Biliary Lipid Concentrations in Gallstone Patients. JAHA. 2018;7(24):e009876. DOI: 10.1161/JAHA.118.009876

  39. Lin X, Racette Susan B, Ma L, Wallendorf M, Ostlund Richard E. Ezetimibe Increases Endogenous Cholesterol Excretion in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37(5):990-6. DOI: 10.1161/ATVBAHA.117.309119

  40. Ben-Aicha S, Badimon L, Vilahur G. Advances in HDL: Much More than Lipid Transporters. Int J Mol Sci. 2020 [acceso: 13/03/2020]; 21(3). Disponible en: https://www.mdpi.com/1422-0067/21/3/732#cite

  41. Muku GE, Kusnadi A, Kuzu G, Tanos R, Murray IA, Gowda K, et al. Selective Ah receptor modulators attenuate NPC1L1-mediated cholesterol uptake through repression of SREBP-2 transcriptional activity. Lab Invest. 2020;100(2):250-64. DOI: 10.1038/s41374-019-0306-x

  42. Wang HH, Portincasa P, de Bari O, Liu KJ, Garruti G, Neuschwander-Tetri BA, et al. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur J Clin Invest. 2013;43(4):413-26. DOI: 10.1111/eci.12058

  43. Wang S, Dong W, Liu L, Xu M, Wang Y, Liu T, et al. Interplay between bile acids and the gut microbiota promotes intestinal carcinogenesis. Mol Carcinog. 2019;58(7):1155-67. PMCID: PMC6593857

  44. Jia E-t, Liu Z-y, Pan M, Lu J-f, Ge Q-y. Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases. J Zhejiang Univ Sci B. 2019;20(10):781-92. DOI: 10.1631/jzus.B1900073

  45. Gil Fortuño M, Granel Villach L, Sabater Vidal S, Soria Martín R, Martínez Ramos D, Escrig Sos J, et al. Biliary microbiote in cholecystectomized patients: Review of empirical antibiotherapy. Rev Esp Quimioter. 2019;32(5):426-31. PMCID: PMC6790889/

  46. Wang Q, Hao C, Yao W, Zhu D, Lu H, Li L, et al. Intestinal flora imbalance affects bile acid metabolism and is associated with gallstone formation. BMC Gastroenterol. 2020;20(1):59. DOI: 10.1186/s12876-020-01195-1

  47. Wang Q, Jiao L, He C, Sun H, Cai Q, Han T, et al. Alteration of gut microbiota in association with cholesterol gallstone formation in mice. BMC Gastroenterol. 2017;17(1):74. DOI: 10.1186/s12876-017-0629-2

  48. Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System. Front Neurosci. 2017 [acceso: 13/03/2020]; 11(617). Disponible en: https://www.frontiersin.org/article/10.3389/fnins.2017.00617




2020     |     www.medigraphic.com